kracht/spierherstel in sporters na krachtspecifieke training Overtraining strength recovery
Conditions
Interventions
Participants will be randomly assigned to one of the intervention groups. Two
groups will receive a daily dose of ovalbumin hydrolysate of either 5 or 10
grams dsitributed over two servings. The fin
Sponsors
BioActor B.V.
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Health individuals (men/women). Participants are amateur or (semi-)professional athletes (engage in >6 hours of intense physical activity per week). Age 18-35. Participants are experienced in resistance training.
Exclusion criteria
Exclusion criteria: - Use of creatine supplements and/or anabolic steroids. - Allergy to test product/protein - Allergy to chicken protein - BMI lower than 18 or higher than 30 - Lack of technique in correctly performing a barbell squat (judged by sports physiologist). - Recent muscle injury in leg or back less than one month before the start of the study. - Cardiovascular complications - Use of medication that may interfere with the study outcomes - Administration of investigational drugs or participation in any scientific intervention study which may interfere with this study (to be decided by the principle investigator), in the 180 days prior to the study. - Abuse of products; alcohol (> 20 alcoholic units per week) and drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary efficacy parameter of the study is to determine the dose-dependent effect of ovalbumin hydrolysate supplementation between two experimental groups compared to placebo for a period of 4 weeks on muscle peak force recovery after high intensity resistance exercise. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints entail the evaluation of dose-dependent effects of daily administration ovalbumin hydrolysate on blood lactate (finger prick), body composition (skin fold measurements), exercise volume, anaerobic capacity, peak force output and delayed onset muscle soreness scores between two experimental groups compared to placebo after a period of 4 weeks. | — |
Countries
Netherlands
Outcome results
None listed